Experimental Hematology & Oncology

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	244
CD44 as a tumor biomarker and therapeutic target	206
Role of m6A writers, erasers and readers in cancer	100
Research progress on dendritic cell vaccines in cancer immunotherapy	82
Heterogeneity of the tumor immune microenvironment and its clinical relevance	73
Breast cancer heterogeneity and its implication in personalized precision therapy	73
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	72
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	69
Engineering better chimeric antigen receptor T cells	68
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	67
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	62
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	61
MiRNA-mediated EMT and CSCs in cancer chemoresistance	54
Recent advances and challenges of bispecific antibodies in solid tumors	52
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	51
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	44
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	43
Current insight into the regulation of PD-L1 in cancer	41
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	41
m6A binding protein YTHDF2 in cancer	41
Increasing cure rates of solid tumors by immune checkpoint inhibitors	40
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	39
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	39
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	39
COVID-19 vaccination associated severe immune thrombocytopenia	38

Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	37
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4	36
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	36
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment	35
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	35
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	34
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma	33
TCR engineered T cells for solid tumor immunotherapy	33
Recent advances in Lynch syndrome	32
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	32
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors	31
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside	27
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas	26
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis	25
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	25
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma	24
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	24
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome	24
New insight into circRNAs: characterization, strategies, and biomedical applications	23
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	23
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	23
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	23
p53 amyloid aggregation in cancer: function, mechanism, and therapy	22
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy	22
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study	22
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia	22
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma	22
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	22
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio	21
RHO GTPase family in hepatocellular carcinoma	21
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer	21
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	21
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review	21
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing	21
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	20
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	20
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	19
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis	19
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	19
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	19
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers	18
Focal adhesion kinase: from biological functions to therapeutic strategies	18
Targeting metabolic reprogramming in chronic lymphocytic leukemia	18
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	18
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	18
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	18
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	17
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	17
The metabolic adaptation mechanism of metastatic organotropism	17

The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	17
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma	17
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion	16
Function and clinical significance of N6-methyladenosine in digestive system tumours	16
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	16
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation	16
Chimeric antigen receptor engineered natural killer cells for cancer therapy	16
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	16
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information	16
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	15
Recent updates for antibody therapy for acute lymphoblastic leukemia	15
The role of organoids in cancer research	15
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma	15
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort	15
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	15
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target	14
Increased TOX expression associates with exhausted T cells in patients with multiple myeloma	14
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU	14
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment	14
Targeting phosphoglycerate dehydrogenase in multiple myeloma	14
Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia	14
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway	13
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	13
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies	12
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	12
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis	12
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	12
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR	12
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway	12
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer	12
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma	11
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients	11
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	11
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells	11
G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway	11
Emerging roles of m6A RNA modification in cancer therapeutic resistance	11
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	11
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	11
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model	11
Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns	11
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	11
Platelet desialylation and TFH cells–the novel pathway of immune thrombocytopenia	11
Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia	10
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	10
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications	10
Recent advances and future perspectives in the therapeutics of prostate cancer	10
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country	10
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML	10
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia	10
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	10
The importance of N6-methyladenosine modification in tumor immunity and immunotherapy	9
Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer	9
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion	9
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis	9
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	9
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	9
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era	8
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	8
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	8
Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA	8
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	8
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	8
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified	8
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression	8
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer	8
Trends in platelet count among cancer patients	8
Cancer metabolism and carcinogenesis	8
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	8
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial	8
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	8
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification	7
Dlk1 maintains adult mice long-term HSCs by activating Notch signaling to restrict mitochondrial metabolism	7
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	7
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	7
Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era	7
Immune checkpoint inhibitors for multiple myeloma immunotherapy	7
Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells	7
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy	7
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications	7
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC	7

Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene	7
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial	7
Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center	7
Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine	7
METTL1 mediated tRNA m7G modification promotes leukaemogenesis of AML via tRNA regulated translational control	7
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation	7
Deciphering tumor-infiltrating dendritic cells in the single-cell era	7
RNA binding proteins in MLL-rearranged leukemia	7
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma	6
Progress in molecular feature of smoldering mantle cell lymphoma	6
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	6
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/re	6
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma	6
Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells	6
Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a	6
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis	6
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide	6
GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis	6
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	6
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma	6
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches	6
A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways	6
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	6
Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia	6
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	6
The roles of tissue resident macrophages in health and cancer	6
Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits	6
Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	5
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases	5
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	5
Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing	5
The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia	5
Secretogranin II influences the assembly and function of MHC class I in melanoma	5
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	5
Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study	5
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells	5
Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis	5
Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing	5
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	5
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	5
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	5
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability	5
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	5
Targeting CD22 for B-cell hematologic malignancies	5
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models	5
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	5
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	5
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	5
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	5
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	5